Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by bigwalleyeon Jun 26, 2010 12:55pm
316 Views
Post# 17224612

RE: RE: RE: Phase III

RE: RE: RE: Phase III

It comes down the FDA believing it has a shot at working. You say limited options? these are the drugs currently in stroke trial https://www.strokecenter.org/trials/index_drugs.aspx . there are lots.

SSS did not invent or own their drug agents what they own is a patented treatment (regimen) that uses two currently approved drugs (hCG & EPO) and they use them in conjunction. They do don't hold the patents on the individual agents used.

From the SCT website

Stem Cell Therapeutics Corp. is a Canadian biotechnology company (TSX-V: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient’s own resident stem cells. The company’s programs aim to repair neurological function lost due to disease or injury.

Our lead program, NTx®-265, is a regimen of two approved and marketed drugs targeting the treatment of stroke. The therapy works by stimulating the growth and differentiation of new neurons to replace the brain cells that are lost or damaged by the stroke and importantly, to direct motor, visual and cognitive recovery after acute ischemic stroke. Our approach avoids surgical transplantation of stem cells; instead we use drugs to stimulate the body’s own existing adult stem cells.

Just showing the facts. We will only know how this all turns out in Oct. I spent a lot of time on this company and I haven't given up but I sold...I'm not telling anyone here to sell just stating the facts. I'm still monitoring and would buy back if it turns the right direction...I've Invested over a year with this company and still think the treatment has merit....but right now has no value to me.

Good luck kid

Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse